Evotec SE (EVOTF) Cash from Investing Activities (2021 - 2026)
Evotec SE's (EVOTF) quarterly Cash from Investing Activities came in at -$14557.1 in Q1 2026, up 35.95% year-on-year from -$10707.6 in Q1 2025, and down 100.01% quarter-over-quarter from $199.8 million in Q4 2025.
Evotec SE (EVOTF) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Evotec SE has disclosed Cash from Investing Activities across 6 years of filings, most recently posting -$14557.1 for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$14557.1, up 35.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $199.8 million (up 362.62% YoY), and the FY2025 annual result was $199.7 million, up 362.57% from the prior year.
- Cash from Investing Activities came in at -$14557.1 for Q1 2026 at Evotec SE, down from $199.8 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $199.8 million in Q4 2025 to a low of -$420.7 million in Q4 2022.
- The 5-year median for Cash from Investing Activities is -$28464.8 (2024), against an average of -$18.3 million.
- Across the five-year window, Cash from Investing Activities slumped 191439.37% in 2022 and surged 362.98% in 2025, its largest moves.
- Evotec SE's Cash from Investing Activities stood at -$420.7 million in 2022, then surged by 96.6% to -$14.3 million in 2023, then plunged by 430.62% to -$76.0 million in 2024, then soared by 362.98% to $199.8 million in 2025, then plunged by 100.01% to -$14557.1 in 2026.
- The last three Cash from Investing Activities figures came in at -$14557.1 (Q1 2026), $199.8 million (Q4 2025), and -$8465.1 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 229.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -87.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 743.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -506.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -60.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -2.08 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -15.45 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 25.99 Mn |
| 10 | Evotec SE | - | - | - | -14,557.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,557.05 |
| Mar 31, 2026 | -14,557.05 |
| Dec 31, 2025 | 199.80 Mn |
| Dec 31, 2025 | 199.80 Mn |
| Sep 30, 2025 | -8,465.13 |
| Sep 30, 2025 | -8,465.13 |
| Jun 30, 2025 | -24,838.59 |
| Jun 30, 2025 | -24,838.59 |
| Mar 31, 2025 | -22,728.07 |
| Mar 31, 2025 | -22,728.07 |
| Dec 31, 2024 | -75.98 Mn |
| Dec 31, 2024 | -75.98 Mn |
| Sep 30, 2024 | -28,464.75 |
| Sep 30, 2024 | -28,464.75 |
| Jun 30, 2024 | -33,687.20 |
| Jun 30, 2024 | -33,687.20 |
| Mar 31, 2024 | -33,576.18 |
| Mar 31, 2024 | -33,576.18 |
| Dec 31, 2023 | -14.32 Mn |
| Dec 31, 2023 | -14.32 Mn |